TL;DR
This study explores the use of fluorescein sodium (FL) as a fluorescent marker to improve the visualization and resection of gangliogliomas, a type of brain tumor. By combining FL with a specialized microscope filter, surgeons were able to better distinguish tumor margins from healthy tissue, leading to a higher rate of complete tumor removal.
What Problem Does This Paper Address?
Gangliogliomas are slow-growing brain tumors that, while often benign, can be challenging to resect completely due to their infiltrative nature and proximity to critical brain structures. Standard surgical techniques rely heavily on visual cues and pre-operative imaging like MRI. While gadolinium-enhanced MRI can highlight these tumors by revealing disruptions in the blood-brain barrier (BBB), intraoperative visualization of tumor margins can still be difficult, potentially leading to incomplete resections and the risk of recurrence. The paper addresses the need for improved intraoperative tools to enhance tumor visualization and maximize the extent of resection, aiming for Gross Total Resection (GTR) whenever possible.
Methods
The researchers conducted a retrospective, multicenter study involving 18 patients who underwent fluorescein-guided resection of gangliogliomas between April 2014 and February 2020. The core of their method involved:
- Fluorescein Sodium (FL) Administration: A dose of 5 mg/kg of FL was administered intravenously to patients after general anesthesia induction, approximately 30-45 minutes before approaching the tumor.
- Specialized Microscopy: The surgical resection was performed using a microsurgical technique with a dedicated YELLOW 560 (YE560) filter on a KINEVO 900 or PENTERO 900 operating microscope. This filter is specifically designed to enhance the fluorescence emitted by FL.
- Intraoperative Assessment: Surgeons subjectively evaluated the degree of FL staining (bright, medium, or absent) and its helpfulness in distinguishing tumor from normal tissue.
- Resection Strategy: Resection continued until the yellow-green staining of the tumor tissue became faint, and pinkish, non-enhancing tissue appeared at the periphery. Care was taken to identify and avoid naturally FL-enhancing structures like the ventricular wall.
- Postoperative Evaluation: The extent of resection was assessed using postoperative contrast-enhanced MRI, with GTR defined as no residual contrast enhancement.
Datasets
The study utilized surgical databases from three neurosurgical departments: Regensburg University Hospital (Germany), Fondazione IRCCS Istituto Neurologico Carlo Besta (Italy), and Liv Hospital (Turkey). The data comprised 18 patients with histopathologically confirmed gangliogliomas who underwent fluorescein-guided surgery. No new datasets were introduced.
Key Insights and Ideas
- FL as a BBB Marker: The study reinforces the idea that FL, like gadolinium, accumulates in areas with a compromised blood-brain barrier (BBB). Since gangliogliomas often disrupt the BBB, FL can effectively highlight these tumorous regions.
- Synergy of FL and Filter: The combination of FL and the YE560 microscope filter appears to be a powerful tool. The filter enhances the visibility of FL, allowing for a significant reduction in the FL dose while still providing clear visualization.
- Improved Intraoperative Navigation: Surgeons consistently found FL to be helpful in distinguishing tumor from healthy tissue, particularly at the tumor margins. This improved visualization directly aids in surgical decision-making.
- Potential for Enhanced Resection: The study suggests that FL-guided surgery can lead to a higher rate of GTR, which is the primary goal in maximizing patient outcomes for these tumors.
Key Results
- Universal Fluorescence: In 100% of the 18 patients, intense yellow-green fluorescent staining of tumor tissue was observed.
- Surgeon Perceived Benefit: In 17 out of 18 cases (94.4%), FL was considered helpful by the operating surgeon for improved resection.
- Gross Total Resection (GTR) Rate: In operations where GTR was considered feasible preoperatively (16 cases), it was achieved in 12 instances (75%). This is comparable to rates reported in other studies for ganglioglioma resection.
- Safety Profile: No side effects or adverse events related to fluorescein administration were encountered during the study period. The only noted effects were transient yellow discoloration of urine and, in some patients, skin.
Limitations and Future Work
- Subjectivity of Fluorescence Assessment: The evaluation of FL fluorescence intensity was subjective, based on surgical reports.
- Retrospective Design: The study's retrospective nature limits definitive conclusions about causality.
- Limited Sample Size: While 18 patients is a reasonable number for a rare tumor type, a larger, prospective study would provide stronger evidence.
- Focus on Contrast-Enhancing Tumors: All tumors in this series showed contrast enhancement on preoperative MRI. The effect of FL on non-enhancing gangliogliomas remains to be elucidated.
- Future Directions: The authors suggest that FL and the YE560 filter are safe and feasible tools for ganglioglioma resection. Further research, including randomized controlled trials, is needed to precisely assess outcomes like recurrence-free and overall survival and to determine optimal FL dosage and timing, especially for redo surgeries. The potential for FL in non-enhancing gangliogliomas also warrants investigation.
Summary updated